Cancer Risk Following ABO Incompatible Living Donor Kidney Transplantation (1)

Details

• Alternative Title:
  Transplantation
• Personal Author:
  Hall, Erin C. ; Engels, Eric A. ; Montgomery, Robert A. ; Segev, Dorry L
• Description:
  Background
  
  Recipients of ABO incompatible (ABOi) living donor kidney transplants often undergo more intense immunosuppression than their ABO compatible (ABOc) counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small, and lack adequate duration of follow-up, to answer this question.
  
  Methods
  
  We identified 318 ABOi recipients in the Cancer Transplant Match Study, a national linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABOc controls by age, gender, race, HLA mismatch, retransplantation, and transplant year.
  
  Results
  
  There was no demonstrable association between ABOi and cancer in unadjusted incidence rate ratio (IRR 0.83, 95% CI 0.33–1.71, p=0.3) or matched control analysis (IRR 0.99, 95% CI 0.38–2.23, p=0.5).
  
  Conclusion
  
  To the extent that could be determined in this registry study, current desensitization protocols are not associated with increased risk of cancer after transplantation.
  
  
• Subjects:
  ABO Blood-Group System Adolescent Adult Aged Antigens, CD20 Article Blood Group Incompatibility Cancer Child Child, Preschool Humans Incompatible Transplantation Infant Infant, Newborn Kidney Transplantation Living Donor Kidney Transplantation Living Donors Middle Aged Neoplasms Risk

  More +
• Source:
  Transplantation. 96(5):476-479.
• Pubmed ID:
  23799426
• Pubmed Central ID:
  PMC3759597
• Document Type:
  Journal Article
• Funding:
  HHSN261201000037C/CA/NCI NIH HHS/United States ; N01PC35143/CA/NCI NIH HHS/United States ; U58 DP000805/DP/NCCDPHP CDC HHS/United States ; U58 DP000817/DP/NCCDPHP CDC HHS/United States ; HHSN261201000035C/CA/NCI NIH HHS/United States ; HHSN261201000036C/CA/NCI NIH HHS/United States ; N01PC35137/CA/NCI NIH HHS/United States ; T32CA126607/CA/NCI NIH HHS/United States ; U58 DP000807/DP/NCCDPHP CDC HHS/United States ; U58 DP000808/DP/NCCDPHP CDC HHS/United States ; T32 CA126607/CA/NCI NIH HHS/United States ; N01PC35142/CA/NCI NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; U58 DP000848/DP/NCCDPHP CDC HHS/United States ; U58 DP000812/DP/NCCDPHP CDC HHS/United States ; HHSN261201000024C/CA/NCI NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; N01PC54405/CA/NCI NIH HHS/United States ; U58 DP000832/DP/NCCDPHP CDC HHS/United States ; N01PC35139/CA/NCI NIH HHS/United States ; HHSN261201000026C/CA/NCI NIH HHS/United States ; U58 DP000824/DP/NCCDPHP CDC HHS/United States
• Volume:
  96
• Issue:
  5
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:e5fae1410618ac1452f7e2d74019edeccb0caf2d7be1548d0aaf6bbe85727d07
• Download URL:
  https://stacks.cdc.gov/view/cdc/41909/cdc_41909_DS1.pdf
• File Type:
  [PDF - 40.21 KB ]